Regencell Bioscience Holdings Limited
RGC
Category
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -343.64 | -85.38% |
| 2025 | -2.35K | 24,110.77% |
| 2024 | -9.71 | -80.99% |
| 2023 | -51.07 | -15.81% |
| 2022 | -60.66 | -38.46% |
| 2021 | -98.57 | -39.68% |
| 2020 | -163.40 | -51.87% |
| 2019 | -339.51 | 0.00% |
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | -110.17% |
IN
|
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.